Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications ...

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...

Andelyn currently offers both adherent and suspension mode manufacturing of research grade AAV vectors up to 200 L in scale, to support preclinical studies including viral vector process and ...

However, scaling up AAV manufacturing to obtain sufficient yields to meet the demands of new research initiatives and clinical applications is challenging using traditional approaches. Download this ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...

The AAV vector manufacturing market is growing by leaps and bounds as the demand for gene and cell therapies is progressing rapidly. VANCOUVER, BRITISH COLUMBIA, CANADA, January 16, 2025 ...

Press releaseGenethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

Adeno-associated viral (AAV) vectors in particular have high transduction rates and reduced toxicity concerns compared to other viral vectors. However, these delivery vehicles present some application ...